Sugi Predict

Sugi Predict / Compounds / SCHEMBL4016418

SCHEMBL4016418

SCHEMBL4016418

CC(O)Cn1c(=O)c(Oc2ccc(F)cc2F)nc2[nH]nc(-c3cc(F)ccc3F)c21

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LPAR2 Q9HBW0 1/20 0.38
▸ MAPK14 Q16539 13/20 0.37
▸ MAPK11 Q15759 2/20 0.36
▸ MAPK8 P45983 2/20 0.35
▸ MET P08581 2/20 0.35
▸ AXL P30530 2/20 0.35
▸ TYRO3 Q06418 2/20 0.35
▸ MERTK Q12866 2/20 0.35
▸ BRD4 O60885 3/20 0.35
▸ RPS6KA4 O75676 1/20 0.35
▸ MAPK9 P45984 1/20 0.35
▸ CSNK1E P49674 1/20 0.35
▸ RPS6KA3 P51812 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ NLK Q9UBE8 1/20 0.35
▸ CARM1 Q86X55 1/20 0.34
▸ PRMT6 Q96LA8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4761595 0.85 MAPK14 (0.44) LPAR2MAPK14MAPK11
SCHEMBL4014023 0.83 MAPK14 (0.48) LPAR2MAPK14MAPK8BRD4
SCHEMBL4011943 0.81 MAPK14 (0.40) LPAR2MAPK14METAXLTYRO3
SCHEMBL4014906 0.73 NPBWR1 (0.38) LPAR2MAPK14MAPK11MAPK8BRD4
SCHEMBL4015197 0.70 MAPK14 (0.46) LPAR2MAPK14MAPK11METAXL
SCHEMBL13764814 0.70 MAPK14 (0.46) LPAR2MAPK14MAPK11METAXL
SCHEMBL4020032 0.66 MAPK14 (0.43) LPAR2MAPK14MAPK11BRD4
SCHEMBL4014863 0.65 TGFBR1 (0.40) MAPK14MAPK11MAPK8CARM1PRMT6
SCHEMBL3016866 0.65 MAPK14 (0.69) MAPK14MAPK11MAPK8RPS6KA4MAPK9
SCHEMBL2948114 0.65 MAPK14 (0.52) MAPK14MAPK11MAPK8RPS6KA4MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US claimed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same MAPKAPK2, MAPK1, MAP3K2 LPAR2 960/4885MAPK14 33/4885MAPK11 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.